Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-12-19, Stock:PFE, The news for the past five days is as follows:
2019-12-12: NEWS1: FDA Approves XELJANZ® XR (tofacitinib) Extended-Release Tablets for the Treatment of Ulcerative Colitis.NEWS2: Iterum Down as Sulopenem Antibiotic Fails in Phase III Study.NEWS3: Big Pharma’s Coming Back in 2020. Don’t Hold Your Breath for Generic Drug Stocks.
2019-12-13: NEWS1: Retired NFL players accused of $3M health benefits scam.NEWS2: Biotech Stocks Burn A Hole In Big Pharma's Pocket; Look For More Mergers In 2020.NEWS3: Dow's 50-point drop led by losses in shares of Verizon Communications Inc., Dow Inc..NEWS4: Jabil (JBL) to Report Q1 Earnings: What's in the Cards?.NEWS5: Sarepta's Vyondys 53 Receives FDA Approval for DMD, Stock Up.NEWS6: Pfizer Receives Positive CHMP Opinion for VYNDAQEL® for Use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare and Fatal Disease.NEWS7: The Daily Biotech Pulse: Second Time's The Charm For Sarepta, Pfizer's Xeljanz Snags Third Approval, NewLink Genetics Rejects Competing Offer.NEWS8: Pharma Stock Roundup: MRK, SNY to Buy Cancer Firms, LLY Starts New Lung Cancer Study.
2019-12-16: NEWS1: Pfizer stock ticks higher on new FDA approval for prostate cancer drug.NEWS2: US Indexes Close at New Highs Monday.NEWS3: XTANDI® (enzalutamide) Approved by U.S. FDA for the Treatment of Metastatic Castration-Sensitive Prostate Cancer.NEWS4: XTANDI® (enzalutamide) Approved by U.S. FDA for the Treatment of Metastatic Castration-Sensitive Prostate Cancer.NEWS5: Dow Jones Today: Lots of Headlines to Digest.NEWS6: Pfizer Gets CHMP Nod for Vyndaqel Label Expansion in Europe.NEWS7: Amarin’s fish-oil pill now available to millions more patients. But it’s still no Lipitor.NEWS8: Amarin’s Vascepa Approval Seems Fishy for Patients and AMRN Investors.NEWS9: Dow jumps nearly 150 points on gains for Goldman Sachs, Cisco stocks.NEWS10: Pfizer raises dividend by nearly 6%, stock gains.NEWS11: Pfizer Declares First-Quarter 2020 Dividend and Announces Upcoming Investor Day to Highlight Strength of Innovative R&D Pipeline.NEWS12: Lilly's Cyramza Gets CHMP Recommendation for First-Line NSCLC.NEWS13: CFRX: Financing Raises $12 Million, including $3 Million from Pfizer….
2019-12-17: NEWS1: Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know.NEWS2: Colorado life science companies brought in more than $12 billion in 2019.NEWS3: S&P 500, Dow and Nasdaq score fresh records at close.NEWS4: Morphic Holding Tabbed as Likely to Develop Blockbuster Drug.NEWS5: Pfizer wins FDA approval for 'first and only' oral treatment for prostate cancer drug.NEWS6: Pfizer Invites Public to View and Listen to Webcast of January 28 Conference Call with Analysts.NEWS7: Pfizer's Xtandi Gets FDA Nod for Expanded Patient Group.NEWS8: The Daily Biotech Pulse: Roche Gets US Antitrust Clearance For Spark Purchase, An Orphan Drug Designation For Prevail, Dynavax Names CEO.NEWS9: Markets Extend Rally, Led by Tech Sector.
2019-12-18: NEWS1: 3 Top Dogs of the Dow Stocks to Own Heading Into 2020.NEWS2: U.S. FDA Accepts and Grants Priority Review to sNDA for BRAFTOVI® (encorafenib) in Combination with ERBITUX® (cetuximab) (BRAFTOVI Doublet) for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer After Prior Therapy.NEWS3: Pfizer and Mylan Announce Two Future Viatris Board Members.NEWS4: Lilly's Stock Up on Upbeat Sales & Profit Outlook for 2020.

Answer: Rise